San Antonio, Texas-based Fountainhead Investment Partners is transitioning from an angel fund to a venture capital firm to provide a broader support to tech startups.
Founded in 2014, Fountainhead Investment Partners aims to connect advancing technologies in order to solve some of medicines’ most complex issues.
Led by Brian Kieser, Managing Partner, the firm will continue to focus on investing in early-stage companies in areas of medical devices, surgical tools, multicellular biologics, regenerative technologies, medical knowledge management and 3D printing.
Investments range from $250k to $1m.
Fountainhead’s initial portfolio company investment was in the AmnioLife Corporation, a human cells, tissues, and cellular-based products developer, based in Gainesville, Fla. The firm led AmnioLife’s Series A funding round of $833,000 with an investment of $750,000.
The angel fund is now closed with $1m in committed capital and will be managed by Fountainhead Investment Partners.
FinSMEs
22/09/2015